RE: What next?16 Oct 2019 14:25
What are the "BAs" and what has the company got now that it didn't back then, other than the efficacy data of the RP trial showing any benefit has now peaked and that they are looking at only a short-term benefit? Admittedly the sample is extremely small but this is an issue as a licence won't be granted on the data available. This means significant R&D expenditure and time before they can take their IP to market.